New drug cocktail aims to shrink melanoma before surgery
NCT ID NCT07336979
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether giving a combination of chemotherapy (paclitaxel polymersomes and carboplatin) plus an immunotherapy drug (adebelimab) before surgery can help shrink tumors in people with resectable mucosal melanoma. About 32 participants will receive up to 3 cycles of treatment, then undergo surgery to remove any remaining cancer. The main goal is to see how many patients have a significant reduction in tumor cells after the drug combo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- paclitaxel polymersomes, carboplatin, and adebelimab
- What this could lead to
- If successful, this approach could shrink tumors before surgery, potentially improving survival and reducing recurrence for people with resectable mucosal melanoma.
- What could go wrong
- This is a small, early-phase trial with only 32 participants, so results may not apply to everyone. The drug combination may cause side effects like nerve damage, low blood counts, or immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE MUCOSAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China